Skip to main content

Table 3 Clinical symptomatology reported by the 9 HHT patients with ascertained SarsCov-2 infection

From: Characterization of epidemiological distribution and outcome of COVID-19 in patients with hereditary hemorrhagic telangiectasia: a nationwide retrospective multi-centre study during first wave in Italy

COVID-19, ascertained (n = 9)

Age years-old, mean (SD)

46.22 ± 9.55

 Range

35–65

Gender (Female), n (%)

3 (33.3)

Clinical symptomatology, COVID-19

Fever, n (%)

7/9 (77.8)

Coughing, n (%)

4/9 (44.4)

Headache, n (%)

2/9 (22.2)

Dyspnea, n (%)

4/9 (44.4)

Muscular Pain, n (%)

3/9 (33.3)

Sense of Tiredness/Fatigue, n (%)

5/9 (55.5)

Diarrhoea, n (%)

2/9 (22.2)

Sore Throat, n (%)

2/9 (22.2)

Rhinorrhea, n (%)

0/9

Conjunctivitis, n (%)

0/9

Gustative/olfactory sensory impairment, n (%)

3/9 (33.3)

None (Asymptomatic), n (%)

1/9 (11.1)

Clinical management and outcomes, COVID-19

Rx-confirmed Pneumoniaa, n (%)

4/9 (44.4)

Domiciliar management, n (%)

7/9 (77.8)

Oxygen support therapy at domiciliar regimen, n (%)

0/9

Hospitalization required, n (%)

2/9 (22.2)

Non-invasive ventilation, n (%)

1/9 (11.1)

Invasive ventilation (intubation), n (%)

1/9 (11.1)

Death, n (%)

0/9

  1. aChest radiological investigation was performed in 4 patients only